ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Translational regulator eIF2α in tumor.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Endoplasmic reticulum stress-mediated cell death in spinal cord injury: from molecular mechanisms to therapeutic applications.Frontiers in cell and developmental biology · 2026Review
- Raphin-1 mediates the survival and sensitivity to radiation of pediatric-type diffuse high-grade glioma via phosphorylated eukaryotic initiation factor 2α-dependent and -independent processes.Molecular oncology · 2025Article
- Upregulation of eIF2α by mJournal of cardiovascular translational research · 2024Article
- Endoplasmic reticulum stress-mediated cell death in cardiovascular disease.Cell stress & chaperones · 2024Review
- Effect of eIF2α in Neuronal Injury Induced by High Glucose and the Protective Mechanism of Resveratrol.Molecular neurobiology · 2023Article
- Proteomic and functional characterization of intra-tumor heterogeneity in human endometrial cancer.Cell reports. Medicine · 2022Article
- Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.International journal of molecular sciences · 2022Article
- Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human.Frontiers in cell and developmental biology · 2021Article
- Review
- Small extracellular vesicles convey the stress-induced adaptive responses of melanoma cells.Scientific reports · 2019Article
- Investigating the Proteomic Profile of HT-29 Colon Cancer Cells After Lactobacillus kefiri SGL 13 Exposure Using the SWATH Method.Journal of the American Society for Mass Spectrometry · 2019Article
- Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics.The EPMA journal · 2019Article
- LncRNA EPB41L4A-AS1 regulates glycolysis and glutaminolysis by mediating nucleolar translocation of HDAC2.EBioMedicine · 2019Article
- eIF2α promotes vascular remodeling via autophagy in monocrotaline-induced pulmonary arterial hypertension rats.Drug design, development and therapy · 2019Article
- A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.Nature communications · 2018Article
- Deletion of eIF2β lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth.Cancer biology & therapy · 2017Article
- Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients.Scientific reports · 2017Article
- Proteomic Analysis of Liver Proteins in a Rat Model of Chronic Restraint Stress-Induced Depression.BioMed research international · 2017Article
- A comprehensive characterization of cell cultures and xenografts derived from a human verrucous penile carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Gastric cardia adenocarcinoma microRNA profiling in Chinese patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The eukaryotic translation initiation factor 2α (eIF2α) is the regulatory subunit of eIF2 which can be inactivated by phosphorylation. In the adaptive response to various microenvironmental stresses, phosphorylation of eIF2α (p-eIF2α) by specific kinases significantly downregulates global protein synthesis while selectively upregulates the activating transcription factor 4 (ATF4) translation. The ATF4 is a transcription activator that can translocate into nucleus and upregulate genes involved in amino acid synthesis, redox balance, protein maturation, and degradation which lead to the activation of both autophagy and apoptosis. During tumor progression, adaptive response facilitates tumor cell survival and growth under severe stresses. Therefore, eIF2α phosphorylation significantly promotes tumor progression and resistance to therapy. However, there is also evidence showing that p-eIF2α exerts suppressive effects on tumorigenesis. Current understanding of the roles eIF2α plays in tumor is still incomplete and needs further investigation. This review addresses on the past and current efforts to delineate the molecular mechanisms of eIF2α in tumorigenesis, tumor progression, resistance to therapy, and tumor cachexia as well as the translational promise of therapeutic applications targeting eIF2α-related signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.